synergy pharmaceuticals appoints gary sender as chief financial officer  business wire synergy pharmaceuticals appoints gary sender as chief financial officer download full size small preview thumbnail gary sender executive vice president and chief financial officer synergy pharmaceuticalsphoto business wire paginationprevious paginationnext gary sender executive vice president and chief financial officer synergy pharmaceuticalsphoto business wire full size small preview thumbnail full size small preview thumbnail november    am eastern standard time new yorkbusiness wiresynergy pharmaceuticals inc nasdaqsgyp a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal gi therapies today announced that gary sender has joined the company as executive vice president and chief financial officer mr sender will be responsible for leading synergy’s financial strategy and operations supporting all functions of the organization “gary is a strong leader whose broad experience in small and larger specialty pharmaceutical organizations uniquely qualifies him to lead and build our financial operations as we enter a transformative period in our history” said gary s jacob phd chairman and ceo of synergy “having previously managed financial planning and analysis and strategic growth initiatives of shire’s global commercial businesses gary has a thorough understanding of the exciting opportunities from which synergy is poised to benefit i’m confident he can add significant value as we prepare to successfully enter a growing and dynamic gi market” “i was immediately attracted to the excitement and energy around synergy” said gary sender “the company is approaching a period of immense growth and opportunity with anticipated regulatory filings next year and the commercial launch of plecanatide planned for early  i look forward to working with the synergy team to successfully execute on these goals and continue to drive significant shareholder return” gary sender has over  years of financial leadership experience in the pharmaceutical and biopharmaceutical industries most recently at shire plc from  mr sender served as senior vice president finance supporting its specialty pharmaceuticals business and subsequently its global commercial businesses he was responsible for financial management and support of all commercial areas of shire’s  billion specialty pharmaceutical and rare disease businesses including the gastroenterology business unit with an emphasis on resource allocation financial forecasting business cases and ma prior to joining shire he was the founding cfo of tengion – a biotechnology company in the field of regenerative medicine mr sender spent  years in a number of leadership roles within merck including investor relations ma finance treasury and divisional financial management mr sender holds a bachelor’s degree in finance and information systems from boston university and a master’s degree in industrial administration mba with a concentration in finance from carnegiemellon university about synergy pharmaceuticals inc synergy is a biopharmaceutical company focused on the development and commercialization of novel gi therapies our proprietary gi platform includes two fullyowned latestage clinical assets  plecanatide and dolcanatide we designed both plecanatide and dolcanatide to be pharmacologically superior versions of the naturally occurring human gi peptide uroguanylin which is an important regulator for digestive fluid movement and gut health plecanatide is our first uroguanylin analog being developed for chronic idiopathic constipation cic and irritable bowel syndrome with constipation ibsc in the summer of  we announced positive phase  data from two plecanatide clinical trials for cic we plan to file our first plecanatide new drug application nda for cic in january  plecanatide is also being evaluated in two ongoing phase  ibsc trials dolcanatide is our second uroguanylin analog currently being evaluated in a phase b study for the treatment of ulcerative colitis dolcanatide is designed to have enhanced resistance to proteolysis in intestinal fluid relative to uroguanylin and yet still retain the same physiologic characteristics as natural uroguanylin in november  we announced positive data with dolcanatide from our phase  clinical trial for opioidinduced constipation oic for more information please visit wwwsynergypharmacom forwardlooking statements certain statements in this press release are forwardlooking within the meaning of the private securities litigation reform act of  these statements may be identified by the use of forward looking words such as anticipate planned believe forecast estimated expected and intend among others these forwardlooking statements are based on synergys current expectations and actual results could differ materially there are a number of factors that could cause actual events to differ materially from those indicated by such forwardlooking statements these factors include but are not limited to substantial competition our ability to continue as a going concern our need for additional financing uncertainties of patent protection and litigation uncertainties of government or third party payer reimbursement limited sales and marketing efforts and dependence upon third parties and risks related to failure to obtain fda clearances or approvals and noncompliance with fda regulations as with any pharmaceutical under development there are significant risks in the development regulatory approval and commercialization of new products there are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful investors should read the risk factors set forth in synergys form k for the year ended december   and other periodic reports filed with the securities and exchange commission while the list of factors presented here is considered representative no such list should be considered to be a complete statement of all potential risks and uncertainties unlisted factors may present significant additional obstacles to the realization of forwardlooking statements forwardlooking statements included herein are made as of the date hereof and synergy does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances contacts synergy pharmaceuticalsgem gokmen hopkins 7vp investor relations and corporate communicationsggokmensynergypharmacom release summary synergy pharmaceuticals appoints gary sender as chief financial officer contacts synergy pharmaceuticalsgem gokmen hopkins 7vp investor relations and corporate communicationsggokmensynergypharmacom search advanced news search advanced news search log in sign up synergy pharmaceuticals appoints gary sender as chief financial officer  business wire synergy pharmaceuticals appoints gary sender as chief financial officer download full size small preview thumbnail gary sender executive vice president and chief financial officer synergy pharmaceuticalsphoto business wire paginationprevious paginationnext gary sender executive vice president and chief financial officer synergy pharmaceuticalsphoto business wire full size small preview thumbnail full size small preview thumbnail november    am eastern standard time new yorkbusiness wiresynergy pharmaceuticals inc nasdaqsgyp a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal gi therapies today announced that gary sender has joined the company as executive vice president and chief financial officer mr sender will be responsible for leading synergy’s financial strategy and operations supporting all functions of the organization “gary is a strong leader whose broad experience in small and larger specialty pharmaceutical organizations uniquely qualifies him to lead and build our financial operations as we enter a transformative period in our history” said gary s jacob phd chairman and ceo of synergy “having previously managed financial planning and analysis and strategic growth initiatives of shire’s global commercial businesses gary has a thorough understanding of the exciting opportunities from which synergy is poised to benefit i’m confident he can add significant value as we prepare to successfully enter a growing and dynamic gi market” “i was immediately attracted to the excitement and energy around synergy” said gary sender “the company is approaching a period of immense growth and opportunity with anticipated regulatory filings next year and the commercial launch of plecanatide planned for early  i look forward to working with the synergy team to successfully execute on these goals and continue to drive significant shareholder return” gary sender has over  years of financial leadership experience in the pharmaceutical and biopharmaceutical industries most recently at shire plc from  mr sender served as senior vice president finance supporting its specialty pharmaceuticals business and subsequently its global commercial businesses he was responsible for financial management and support of all commercial areas of shire’s  billion specialty pharmaceutical and rare disease businesses including the gastroenterology business unit with an emphasis on resource allocation financial forecasting business cases and ma prior to joining shire he was the founding cfo of tengion – a biotechnology company in the field of regenerative medicine mr sender spent  years in a number of leadership roles within merck including investor relations ma finance treasury and divisional financial management mr sender holds a bachelor’s degree in finance and information systems from boston university and a master’s degree in industrial administration mba with a concentration in finance from carnegiemellon university about synergy pharmaceuticals inc synergy is a biopharmaceutical company focused on the development and commercialization of novel gi therapies our proprietary gi platform includes two fullyowned latestage clinical assets  plecanatide and dolcanatide we designed both plecanatide and dolcanatide to be pharmacologically superior versions of the naturally occurring human gi peptide uroguanylin which is an important regulator for digestive fluid movement and gut health plecanatide is our first uroguanylin analog being developed for chronic idiopathic constipation cic and irritable bowel syndrome with constipation ibsc in the summer of  we announced positive phase  data from two plecanatide clinical trials for cic we plan to file our first plecanatide new drug application nda for cic in january  plecanatide is also being evaluated in two ongoing phase  ibsc trials dolcanatide is our second uroguanylin analog currently being evaluated in a phase b study for the treatment of ulcerative colitis dolcanatide is designed to have enhanced resistance to proteolysis in intestinal fluid relative to uroguanylin and yet still retain the same physiologic characteristics as natural uroguanylin in november  we announced positive data with dolcanatide from our phase  clinical trial for opioidinduced constipation oic for more information please visit wwwsynergypharmacom forwardlooking statements certain statements in this press release are forwardlooking within the meaning of the private securities litigation reform act of  these statements may be identified by the use of forward looking words such as anticipate planned believe forecast estimated expected and intend among others these forwardlooking statements are based on synergys current expectations and actual results could differ materially there are a number of factors that could cause actual events to differ materially from those indicated by such forwardlooking statements these factors include but are not limited to substantial competition our ability to continue as a going concern our need for additional financing uncertainties of patent protection and litigation uncertainties of government or third party payer reimbursement limited sales and marketing efforts and dependence upon third parties and risks related to failure to obtain fda clearances or approvals and noncompliance with fda regulations as with any pharmaceutical under development there are significant risks in the development regulatory approval and commercialization of new products there are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful investors should read the risk factors set forth in synergys form k for the year ended december   and other periodic reports filed with the securities and exchange commission while the list of factors presented here is considered representative no such list should be considered to be a complete statement of all potential risks and uncertainties unlisted factors may present significant additional obstacles to the realization of forwardlooking statements forwardlooking statements included herein are made as of the date hereof and synergy does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances contacts synergy pharmaceuticalsgem gokmen hopkins 7vp investor relations and corporate communicationsggokmensynergypharmacom release summary synergy pharmaceuticals appoints gary sender as chief financial officer contacts synergy pharmaceuticalsgem gokmen hopkins 7vp investor relations and corporate communicationsggokmensynergypharmacom search advanced news search advanced news search log in sign up gary sender  nabriva therapeutics ag  zoominfocom bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version gary sender at shire limited contact details  leadferretcom login with your social account or  forgot password create a free accountsign up leadferret search contacts specialty directories about us blog company faqs partners careers contact us privacy policy help faq tutorials buy points earn points salesnexus  company  contact directories companies contacts contact details for gary sender gary sender chief financial officer contact information phone   email please log in or register to see the details social links twitter please log in or register to see the details facebook please log in or register to see the details linkedin please log in or register to see the details google please log in or register to see the details company information name shire limited address 7 chesterbrook blvd wayne pa  phone  website httpwwwshirecom view complete company profile claim profile is this you claim your profile to update andor remove this information quality scoreout of  please note this contacts quality score is below our quality threshold this data could be outdated and is not guaranteed to be accurate others with similar first and last names first name last name title company name gary sender chief financial officer and vice president of fina tengion inc gary sender financial director merck  co inc gary sender social studies teacheryearbook fairfax county public schools gary sender arcredit representative graphic paper inc list of colleagues of gary sender at shire limited first name last name title greg hungerford senior sales training specialist james schimelfenig national corporate accounts ricki greenwood senior administrative assistant sheree robinsondavis senior administrative assistant joseph schlitz vice president us commercial lead renal lynda may editor maura dijoseph procrement specialist nina janes senior product manager patricia bagrud benefits analyst shelly wilham administrative assistant romy cayo director of materiais management jeffrey wilson team lead business systems pat sullivan promotion manager harley smith administrator network shire us specialty pharmaceu david reese senior director patty cooney emea matt jenkins senior analyst market research diana costa investor relations stanley newman purchasing nicole griffin marketing specialist matthew handel senior director global business analysis and forec jamie schmid recruitment consultant human resources hilary mandler traininglearning and development manager graham hetherington chief financial officer director gopinath rajendran senior analyst systems shire us specialty pharmace joanna nixon group systems accountant anna hjerdin investor relations heather mccormick accountant sandra immerman information technology senior director megan stobei assistant at shire hgt lauren shamitz purchasing specialist joseph dorazio human resources george kemp product manager shareef jackson senior database analyst gary sender chief financial officer tom mcdonnell marketing director intuniv melissa voulgaris graphic designer tricia jeanmary copyeditor andrea kehler marketing collateral verna saunders emea chek cheng business analyste rebecca hazelton employees issues only rebekah gorney senior clinical research associate afsaneh mohebbi senior program executive mike yasick senior vice president gi business unit danielle bean executive assistant to peter lasky and charlotte s normand rochon supply chain lead marion dallas team lead brett jeffries compensation analyst jeanyves boursier directeur financier e m e a james lyver senior systems architecture analyst jonathan kerbein senior business analyst tiffany cummings professional education consultant educational gran mort sullivan senior clinical document associate hilary mandler traininglearning and development caroline sampson hrms administrator patrick deas clinical scientist janet cooper financial analyst michel florio directeur de vent orwell jacobs sales representative arthur silverberg biostatistician ii ken bryan telecommunications kimberly nesbitt senior accounts payable analyst rabih kyriakos market analyst sean wills clinical report publishing dominick ricci professional education david banchik tech assessment christina campanella senior associate ellen hawkins emea kathryn hoffman khoffmanshire com jessica ryeland trainer deb glancy senior clinical research associate dyane monti adjoint installations christine frank global learning and development felis amaro senior analyst gf and sp jason taylor infrastructure consultant kim bigelow group leader bharat desai clinical scientist marti baker executive assistant john lee president michelle jennings international marketing andrew timofeev shire hgt fran mozloom electronic resources manager kelly fitzpatrick senior quality control analyst  barbara calabro engineeringr and d jeff bailey financial analyst sarah plush business systems analyst jeremy hamelink senior sales training specialist ii nancy moran senior admin assistant debra mercier security specialist tiffany crump senior medical affairs assistant marc weeks online communications specialist jennifer jasper financial analyst leeann shiveley purchasing specialist peter mcgrath senior buyer sales and rose whitford trainer rob stackhouse senior business systems specialist r and d simon cowley information technology business systems manager r mike bandru international marketing steve aaronson senior specialist information systems business man tessa blair lead inspector amber solliday research scientist mike miller senior analyst supply chain jim smith director managed markets debbie mccarthy scientist seth levy emea gin cromer corporate communications julia kirby resolute communications × – a message from leadferret close new message ↑ leadferret chat loading microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext7 about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext7 personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext7 legal privacy  cookies   microsoft nabriva appoints gary sender as chief financial officer nasdaqnbrv english français register sign in nabriva appoints gary sender as chief financial officer may    et  source nabriva therapeutics us inc vienna austria and king of prussia pa may   globe newswire  nabriva therapeutics ag nasdaqnbrv a clinical stage biopharmaceutical company engaged in the research and development of novel antiinfective agents to treat serious infections with a focus on the pleuromutilin class of antibiotics today announced that gary sender has joined the company as chief financial officer mr sender will be responsible for leading nabriva’s financial strategy and operations supporting all functions of the organization “first i want to thank ralf schmid for his great leadership and outstanding contributions he has provided to nabriva since its inception  years ago most recently as chief operating officer and chief financial officer and i wish him well in his next endeavor” said colin broom md ceo of nabriva “i am very excited to bring gary on board as a strong leader whose broad experience with financial planning and strategic analysis in the biopharmaceutical industry appropriately qualifies him to lead and continue to build our financial operations i am confident that he can add significant value as we continue to progress toward our goal of successfully developing and commercializing a novel systemic antibiotic to address an unmet need in the treatment of patients with serious infections” mr schmid has agreed to stay with nabriva until may st in order to transition his current responsibilities and continue to provide consulting services to the company on an as requested basis until the end of august  “i am very impressed by nabriva’s accomplishments over the past year” said gary sender “the company is approaching a transformational opportunity with lefamulin phase  topline data in cabp planned for the second half of  and i look forward to working with the nabriva team to successfully lead its financing strategy and plan for the commercialization of lefamulin while continuing to drive significant shareholder return” gary sender has over  years of financial leadership experience in the pharmaceutical and biopharmaceutical industries most recently as chief financial officer and evp at synergy pharmaceuticals from  mr sender served as senior vice president finance at shire plc supporting its specialty pharmaceuticals business and subsequently its global commercial businesses he was responsible for financial management and support of all commercial areas of shire’s  billion specialty pharmaceutical and rare disease businesses with an emphasis on resource allocation financial forecasting business cases and ma prior to joining shire he was the founding cfo of tengion – a biotechnology company in the field of regenerative medicine mr sender spent  years in a number of leadership roles within merck including investor relations ma finance treasury and divisional financial management mr sender holds a bachelor’s degree in finance and information systems from boston university and a master’s degree in industrial administration mba with a concentration in finance from carnegiemellon university about nabriva therapeutics ag  nabriva therapeutics is a clinical stage biopharmaceutical company engaged in the research and development of novel antiinfective agents to treat serious bacterial infections with a focus on the pleuromutilin class of antibiotics nabrivas medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins including both intravenous and oral formulations of its lead product candidate nabrivas lead pleuromutilin product candidate lefamulin is being developed to be the first systemically available pleuromutilin for human use and is the first new class of antibiotic to reach late stage clinical development for cabp in over a decade nabriva believes lefamulin is well positioned for use as a firstline empiric monotherapy for the treatment of moderate to severe cabp due to its novel mechanism of action targeted spectrum of activity resistance profile achievement of substantial drug concentration in lung tissue and fluid oral and iv formulations and favorable tolerability profile nabriva also intends to further pursue the development of lefamulin for additional indications including the treatment of acute bacterial skin and skin structure infections and is developing a formulation of lefamulin appropriate for pediatric use nabriva owns exclusive worldwide rights to lefamulin which is protected by composition of matter patents issued in the united states europe and japan forward looking statements any statements in this press release about future expectations plans and prospects for nabriva including but not limited to statements about the development of nabriva’s product candidates such as plans for the design conduct and timelines of phase  clinical trials of lefamulin for cabp the clinical utility of lefamulin for cabp and nabriva’s plans for filing of regulatory approvals and efforts to bring lefamulin to market the development of lefamulin for additional indications the development of additional formulations of lefamulin plans to pursue research and development of other product candidates and other statements containing the words “anticipate” “believe” “estimate” “expect” “intend” “may” “plan” “predict” “project” “target” “potential” “likely” “will” “would” “could” “should” “continue” and similar expressions constitute forwardlooking statements within the meaning of the private securities litigation reform act of  actual results may differ materially from those indicated by such forwardlooking statements as a result of various important factors including the uncertainties inherent in the initiation and conduct of clinical trials availability and timing of data from clinical trials whether results of early clinical trials or trials in different disease indications will be indicative of the results of ongoing or future trials uncertainties associated with regulatory review of clinical trials and applications for marketing approvals the availability or commercial potential of product candidates including lefamulin for use as a firstline empiric monotherapy for the treatment of moderate to severe cabp the sufficiency of cash resources and need for additional financing and such other important factors as are set forth under the caption risk factors in nabriva’s annual report on form f as filed with the united states securities and exchange commission in addition the forwardlooking statements included in this press release represent nabriva’s views as of the date of this release nabriva anticipates that subsequent events and developments will cause its views to change however while nabriva may elect to update these forwardlooking statements at some point in the future it specifically disclaims any obligation to do so these forwardlooking statements should not be relied upon as representing nabriva’s views as of any date subsequent to the date of this releasecontact will sargent nabriva therapeutics ag williamsargentnabrivacom related articles other press releases by nabriva therapeutics us inc nabriva therapeutics appoints francesco maria lavino as chief commercial officer july    nabriva therapeutics appoints carrie bourdow and colin broom to the board june    nabriva therapeutics plc successfully concludes tender offer for outstanding common shares of nabriva therapeutics ag and outstanding american depositary shares of nabriva therapeutics ag june    nabriva therapeutics announces webcast of analyst  investor day on june   june    nabriva therapeutics to present data at asm microbe supporting ongoing phase  clinical development program for lefamulin june     other news releases in directors and officers in the last  days profile nabriva therapeutics us inc   subscribe via rss  subscribe via atom  javascript king of prussia pennsylvania united states   httpwwwnabrivacom contact data contact will sargent nabriva therapeutics ag williamsargentnabrivacom contact with a reader account its easy to send email directly to the contact for this release sign up today for your free reader account already have an account log in here media files nabriva therapeutics us inc logo logo url  copy the link below formats available original medium small newswire distribution network  management home newsroom rss feeds legal contact us about us globenewswire a nasdaq company is one of the worlds largest newswire distribution networks specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media investment community individual investors and the general public contact us corporate headquarters  rosecrans avenue suite  el segundo ca  phone  7 fax  7 european headquarters woolgate exchange  basinghall street london ecv ha uk phone     globenewswire inc all rights reserved gary sender – cfo moves cfo movestracking cfo movement across the usa cfo moves – week ending april   posted on may   written by samuel dergel leave a comment cfo moves this week include yum brands inc hilton worldwide anaplan ampcopittsburgh corporation groupon synergy pharmaceuticals inc benefitfocus inc grange insurance social reality inc ani pharmaceuticals inc penn community bank brixmor property group inc bear state financial inc unum group tangoe inc cadence design systems inc bask technology inc supervalu inc safeware icertis seychelle water filtration products lee industries inc ddr corp excel trust amrep corporation brightcove inc msci inc watt companies vantiv inc frequency electronics inc first midwest bancorp inc ikegps eyegate pharmaceuticals inc mod pizza omnitracs llc wilhelmina international inc manhattan associates inc   would you like to receive our weekly cfo moves directly in your email click the sign me up button on the right of the blog page should you have any cfo moves to report please email us new cfo search report available monthly to cfos only read more here cfo moves is published by samuel dergel executive search consultant and cfo  financial executive search specialist with dergel executive search samuel can be reached by email at samueldergelcfocom or by phone at   7                                      yum brands inc louisville ky nyse yum announced the promotion of david gibbs to president and chief financial officer he previously served as chief executive officer of the global pizza hut division he served as cfo of pizza hut us from  to  before transitioning to a global role as president and cfo of yum restaurants international gibbs also served as president of pizza hut us prior to assuming the role of division ceo hilton worldwide mclean va nyse hlt announced the appointment of sean m dell’orto as chief financial officer of the planned real estate investment trust reit that is expected to form following its separation from hilton worldwide later this year dell’orto will continue to serve as senior vice president and treasurer for hilton worldwide previously dell’orto was senior vice president and chief financial officer of barceló crestline corporation and was vice president and treasurer at highland hospitality corporation anaplan san francisco announced it has appointed david f conte to its board of directors he is currently chief financial officer cfo and senior vice president at splunk inc previously he served as cfo at ironkey inc prior to that he served as cfo at software company opsware ampcopittsburgh corporation carnegie pa nyse ap announced the appointment of michael g mcauley as chief financial officer cfo and treasurer he most recently served as senior vice president and cfo at rti international metals rti before joining rti mr mcauley held positions of increasing responsibility at goodrich corporation and air products and chemicals inc groupon chicago nasdaq grpn announced that it has named mike randolfi as its chief financial officer randolfi most recently served as cfo of orbitz worldwide prior to orbitz randolfi held a number of senior finance roles at delta air lines ultimately serving as senior vice president and controller synergy pharmaceuticals inc new york nasdaq sgyp announced that gary l sender has resigned as the company’s chief financial officer bernard f denoyer who has served as senior vice president of finance and secretary at synergy since  will assume responsibilities as principal financial officer benefitfocus inc charleston sc nasdaq bnft announced that dennis b story will join the company as chief financial officer story is currently executive vice president and chief financial officer of manhattan associates inc and has been with manhattan associates since march of  he was previously senior vice president of finance for certegy until its merger with fidelity national information services inc prior to certegy story held the cfo role at newroads inc and also previously served as a senior vice president with equifax story began his career at coopers  lybrand grange insurance columbus ohio announced that terri dalenta has joined the company as executive vice president chief financial officer she most recently served as svp of property product management for allstate insurance in chicago prior to allstate dalenta served as evp and chief risk officer for aviva north america and then served in the company’s london headquarters as risk framework director she also previously served as chief risk officer and corporate chief actuary for safeco insurance terri started her career in the late s with aetna life and casualty she’s also held senior positions with deloitte consulting llp and travelers insurance social reality inc los angeles otcqb scri announced the appointment of rahul thumati as its chief financial officer he joins the company from liberman broadcasting there he served as corporate controller and vp of finance from august  until joining social reality in march  prior to working at liberman broadcasting mr thumati held a variety of executive finance positions including his post as corporate controller of evergreen studios previous to that he also served as corporate controller for forward industries mr thumati was employed by the walt disney company from november  until september  serving as senior manager corporate accounting and manager transaction support from november  until november   prior to that he was employed by deloitte  touche serving as senior consultant – regulatory and capital markets consulting ani pharmaceuticals inc baudette minn nasdaq anip announced the appointment of stephen p carey to the position of vice president and chief financial officer steve has held various financial and accounting positions with schering plough corporation and most recently par pharmaceutical companies inc where he was the senior vice president controller and principal accounting officer steve began his career at pricewaterhousecoopers penn community bank doylestown pa announced that it has hired stephanie a austin as its chief financial officer austin previously served as chief financial officer and treasurer for continental bank holdings inc for nine years prior to that austin served as the controller at harleysville national bank she previously had served as the controller for progress financial group brixmor property group inc new york nyse brx announced that it named angela aman as chief financial officer ms aman will succeed barry lefkowitz mr lefkowitz has held the position on an interim basis since february  ms aman currently serves as executive vice president and chief financial officer of starwood retail partners previously she served as the executive vice president chief financial officer and treasurer of retail properties of america inc she previously served as a portfolio manager with rreef and started her career in the real estate practice in the investment banking group at deutsche bank bear state financial inc little rock ark nasdaq bsf announced that chief accounting officer sherri billings was named senior executive vice president chief financial officer and chief accounting officer mrs billings has been with the bank since 7 she has served as an executive vice president since  and became chief accounting officer in  she previously served as chief financial officer of the company and first federal bank from  until  as senior vice president for first federal bank from  to  and as treasurer for first federal bank from  to  unum group chattanooga tenn nyse unm announced that josh nelson will be joining the company as chief financial officer of its colonial life business nelson joins unum group from metlife where he most recently served as vice president and chief financial officer he previously held leadership roles at the hartford and aig tangoe inc orange conn nasdaq tngo announced that jay zager will assume responsibility as the company’s interim chief financial officer after former cfo gary martino resigned mr zager most recently served as executive vice president and chief financial officer of axcelis technologies acls from which he retired in  prior to this role mr zager served as executive vice president and chief financial officer at com corporation cadence design systems inc san jose calif nasdaq cdns announced that geoff ribar senior vice president and chief financial officer who joined the company in  has decided to retire bask technology inc lehi utah announced that phil fraher has been hired as chief financial officer before joining bask he served as ceo coo and cfo for houstonbased fuelquest president and ceo of visual numerics inc coo and cfo of brightmail inc and held other financial management positions at cahners business information electronic media division pilot software and dun  bradstreet in addition fraher has been a key advisor to several emerging startup organizations and previously served as an executive in residence at the houston technology center supervalu inc eden prairie minn nysesvu announced that mary winston has been appointed to supervalu’s board of directors ms winston joins the board having most recently served from  through august  as the executive vice president and chief financial officer for family dollar stores inc before joining family dollar from  to  ms winston served as senior vice president and chief financial officer for giant eagle inc ms winston currently serves on the boards of directors for dover corporation and domtar corporation and from  through february  was a director for plexus corporation safeware dublin ohio welcomes michael newcomb as its new chief financial officer newcomb joins safeware companies like cardinal health expressmed and igb icertis bellevue wash announced the addition of jeff epstein operating partner at bessemer venture partners bvp to its advisory board epstein the former executive vice president and chief financial officer at oracle seychelle water filtration products san juan capistrano calif otcqb syev announced that james place will become president and remains cfo lee industries inc philipsburg pa announced the appointment of joshua t montler as president and chief financial officer and chief operating officer joshua montler has served as vice president of finance and operations for the company since  and will succeed his fatherrobert w montler as president robert montler will remain chairman of the board and chief executive officer prior to joining lee industries he was a senior cost accountant for first quality corporation in great neck ny previously he was a cost accountant with denver colobased gates corporation he earlier served as an accountant for young oaks brown  company ddr corp beachwood ohio nyse ddr announced that chief financial officer and treasurer luke j petherbridge will step down from his role david j oakes will also serve as chief financial officer and treasurer on an interim basis until a successor is appointed excel trust san diego  new york announced its appointment of luke j petherbridge as chief executive officer and president mr petherbridge is an experienced retail real estate executive and currently serves as the chief financial officer and treasurer of ddr corp amrep corporation princeton nj nyse axr announced that pete pizza will retire as chief financial officer of amrep clifford martin currently amrep’s treasurer and director of accounting will assume the role of chief financial officer brightcove inc boston nasdaq bcov announced that gary haroian has been named chairman of the board of directors mr haroian’s has served as the chief executive officer and chief financial officer for several public software companies including serving as the chief financial officer of bowstreet and concord communications and as chief executive officer of stratus computer in addition he currently serves on the board of directors of aspen technologies and enernoc and has previously served on the boards of directors of a systems network engines unica corporation phase forward authorizenet holdings and embarcadero technologies msci inc new york nyse msci announced that kathleen winters will join the firm as chief financial officer she will succeed bob qutub who is retiring from the firm ms winters joins msci from honeywell international where she most recently served as vice president and chief financial officer ms winters began her career at pricewaterhousecoopers where she held various positions from  to  watt companies los angeles announced that brian burdzinski has been promoted from vice president to chief financial officer prior to joining watt brian led finance operations at john laing homes and western pacific housing vantiv inc cincinnati nyse vntv announced that stephanie ferris has been promoted to chief financial officer ferris joined vantiv in  as senior vice president in  she was tapped to be general manager of the company’s merchant bank business before vantiv’s spinoff from fifth third bank in  ferris spent  years serving the bank in various leadership positions including as chief financial officer of fifth third processing solutions prior to fifth third ferris worked in public accounting at pricewaterhousecoopers frequency electronics inc mitchel field ny nasdaqfeim announced that alan miller will step down as secretary treasurer and chief financial officer first midwest bancorp inc itasca il nasdaq fmbi announced that paul f clemens chief financial officer of the company and its subsidiary first midwest bank has advised the company that he will be retiring ikegps broomfield co announced the appointment of dennis bencala as its chief financial officer bencala has served as cfo and vice president of finance at nasdaqlisted ikanos communication inc cfo and corporate controller of nasdaqlisted sirf technology holdings inc cfo at venture capitalbacked renewable energy test center inc and corporate controller of venture capitalbacked and hong konglisted scanvision inc eyegate pharmaceuticals inc waltham mass nasdaq eyeg announced the appointment of ryan r brenneman as its chief financial officer prior to joining eyegate mr brenneman served as senior vice president and chief accounting officer at cys investments inc previously he was managing director and chief accounting officer at first marblehead corporation he spent over four years at freddie mac where he served as controller – multifamily accounting and controller – investments and capital markets accounting he has also held seniorlevel finance positions at organizations including booz allen hamilton protiviti inc intersystems corporation and nervewire inc and has served as an independent cfo consultant to several companies in the boston area mod pizza seattle wa announced the appointment of bob barton to the role of chief financial officer barton was cfo and vp of operations for nine years at drugstorecom and president coo and cfo of onlineshoescom omnitracs llc dallas announced the appointment of sarah hagan as chief financial officer prior to joining omnitracs hagan spent  years at sabre corporation she also served as vice president of finance for a 7m division that develops software solutions for the airline industry  earlier in her career she was an auditor with public accounting firm rco wilhelmina international inc new york announced that james mccarthy has been named the company’s chief financial officer most recently mccarthy has served as controller of orchard media inc august  to april  earlier in his career he worked at ernst  young llp in new york manhattan associates inc atlanta nasdaq manh announced that the company’s executive vice president chief financial officer and treasurer dennis b story notified the company he will be leaving to pursue personal and other business interests the company intends that linda c pinne senior vice president global corporate controller and chief accounting officer will serve as manhattan’s interim cfo until mr story’s successor is in place share thislinkedintwitterfacebookgoogleemailprintlike thislike loadingcfo moves – week ending november   posted on november   written by samuel dergel leave a comment cfo moves this week include adtran inc microline surgical peoples bancorp inc limelight networks inc trion solutions inc biotime inc the priceline group shorr packaging corp seegrid endogastric solutions nantkwest inc spectralink corporation scientific games corporation synergy pharmaceuticals inc bracket impossible foods inc lantronix inc clutch accuride corporation the whitewave foods company hanmi financial corporation costar group inc francesca’s holdings corporation   would you like to receive our weekly cfo moves directly in your email click the sign me up button on the right of the blog page should you have any cfo moves to report please email us cfo moves is published by samuel dergel executive search consultant and cfo  financial executive search specialist with stanton chase samuel can be reached by email at sdergelstantonchasecom or by phone at   7                                      adtran inc nasdaq adtn huntsville ala announced it has appointed roger d shannon as its senior vice president of finance and chief financial officer cfo prior to joining adtran shannon served as cfo and treasurer at steel technologies llc a subsidiary of mitsui  co ltd and nucor corporation since july  also serving as its principal accounting officer prior to his nineyear tenure at steel technologies shannon directed global treasury for brownforman corporation microline surgical beverly ma announced the appointment of joseph falcao as chief financial officer prior to joining microline surgical joe worked for several wellknown boston companies including cabot corporation dunkin brands invensys ibasis and mccue peoples bancorp inc nasdaq pebo marietta ohio announced the appointment of john c rogers to the position of executive vice president chief financial officer and treasurer of peoples and its banking subsidiary peoples bank national association “peoples bank” effective november   rogers worked most recently for pnc financial services group inc in pittsburgh pennsylvania from  until october of  he served as risk executive from  to  from  to  he served as executive vice president and chief financial officer retail business banking and from  to  he served as vice president and chief financial officer consumer lending rogers replaces edward g sloane who resigned in order to pursue other career opportunities limelight networks inc nasdaq llnw tempe ariz announced that pete perrone has informed the company of his intent to resign his duties as chief financial officer effective december   sajid malhotra limelight’s chief strategy officer has been named interim cfo effective december   mr malhotra joined the company in april  as the senior vice president in charge of strategy facilities investor relations and procurement he was promoted to chief strategy officer in june  trion solutions inc troy mich has named andrew w kirk as executive vice president and chief financial officer prior to joining trion kirk served as an advisor to nonprofit firms and emerging businesses kirk previously served as president of the michiganbased belle tire distributors inc biotime inc nyse mkt and tase btx alameda calif announced that the company’s board of directors has appointed russell skibsted to the position of chief financial officer succeeding robert peabody prior to joining the biotime team russell was cfo at proove biosciences previously he was senior vice president cfo and secretary of aeolus pharmaceuticals he also served as svp and chief business officer of spectrum pharmaceuticals earlier in his career mr skibsted was partner and cfo at asset management company  the priceline group nasdaq pcln norwalk conn announced that christa quarles has been named chief executive officer of opentable quarles has served as the chief financial officer of opentable since may  and as interim ceo since september of  when former ceo matt roberts moved into the role of chairman opentable prior to joining opentable in  quarles served as the chief business officer for nextdoor previously she served as the svp and general manager at disney where she led the mobile and social games divisions within disney interactive shorr packaging corp aurora ill announced the promotion of kevin vrba to chief financial officer cfo vrba began working at shorr as the controller in march   prior to that he held senior finance roles at coopers hawk topgolf and bar louie after spending  years in public accounting at crowe horwath seegrid pittsburgh pa announced it has appointed ed henry to serve as the company’s chief financial officer he previously served as chief financial officer at vista resources inc and as director of finance at thermo fisher scientific before joining the company endogastric solutions redmond wash announced that michael k burke has been named chief financial officer he most recently served as senior vice president and chief financial officer of landauer inc prior to this he was the senior vice president and chief financial officer of albany international corp and as the executive vice president and chief financial officer of intermagnetics general corporation nantkwest inc nasdaq nk culver city calif announced the appointment of angela wilson as chief financial officer cfo wilson first joined nantkwest in october  as vice president finance previously wilson served as vice president finance and controller for virgin galactic she began her professional career and served for  years with ernst  young ey spectralink corporation boulder co announced that casey hofmann has joined the company’s management team as chief financial officer prior to joining spectralink casey served as cfo for sun capital partners portfolio company american recreation products llc and its newly formed entity exxel outdoors llc earlier she held various other cfo and financial management positions for technology manufacturing and consumer products companies scientific games corporation nasdaq sgms las vegas announced that scott d schweinfurth executive vice president chief financial officer and corporate secretary will be retiring from the company synergy pharmaceuticals inc nasdaq sgyp new york announced that gary sender has joined the company as executive vice president and chief financial officer gary sender previously served as senior vice president finance of shire plc prior to joining shire he was the founding cfo of tengion before that he spent  years in a number of leadership roles within merck bracket wayne pa announced the addition of j matthew bond as chief financial officer most recently matt cofounded and served as the cfo of aptiv solutions previously matt was executive vice president and cfo of a global growth oriented cro impossible foods inc redwood city calif announced today that david lee will become the company’s new chief operating officer and chief financial officer lee served most recently as cfo of zynga prior to that he served as the senior vice president of enterprise finance for best buy during his eight years at del monte he held several leadership positions across finance and general management including senior vice president of strategy and earlier served as senior vice president of consumer products lantronix inc nasdaq ltrx irvine ca announced that chief financial officer jeremy whitaker has been appointed interim chief executive officer of the company whitaker will continue to serve as chief financial officer of the company a position he has held since september  before joining the company as chief financial officer he served as vice president corporate controller at mindspeed technologies from january  to september  prior to that whitaker served in a number of finance and accounting roles at lantronix from august  to january  including as vice president of finance and accounting senior director of finance and director of finance and accounting clutch philadelphia recently brought on mark s pollock as the company’s chief financial officer prior to joining clutch pollock spent three years with mng direct prior to that he worked for an array of startup growth and turnaround companies like portico avanceon and vertical alliance accuride corporation nyse acw evansville ind announced that michael a hajost will join accuride as senior vice president and chief financial officer michael previously served as vice president treasury and investor relations for carpenter technology corp previously he had served as vice president treasurer jbs swift  company of greeley colo he began his corporate career with eli lilly and company of indianapolis ind after completing five years of service as an officer in the us army the whitewave foods company nyse wwav denver colo announced that chief financial officer kelly haecker has decided to leave the company effective march   to spend more personal time with his family haecker will ensure a smooth transition of his responsibilities to greg christenson who will be promoted to executive vice president chief financial officer of whitewave effective april   christenson  has served as senior vice president and chief financial officer americas foods  beverages since june  prior to joining whitewave christenson was vice president and chief financial officer of oberto brands from january  to june  before that christenson spent  years at kraft foods inc most recently as director of finance cheese hanmi financial corporation delaware reported that romolo “ron” c santarosa was appointed senior executive vice president and chief financial officer of the company and the bank mr santarosa has served as senior executive vice president corporate finance and strategy of the company and the bank since june   most recently from june  – june  he was executive vice president and chief operating officer at opus bank before that he served as the senior executive vice president chief financial officer and chief operating officer at first california financial group inc and its bank subsidiary first california bank from november  to may  costar group inc nasdaq csgp washington dc announced the appointment of scott wheeler as chief financial officer of the company effective january   wheeler has served in various roles with experian since  including his most recent role of chief financial officer – experian north america and global technology services from  through  mr wheeler served as chief financial officer – experian north america director – salesshare and innovation from  through 7 mr wheeler served as chief financial officer – experian americas mr wheeler comes to costar with thirty years of financial and leadership experience including ten years with deloitte  touche llp francesca’s holdings corporation nasdaq fran houston announced that its chief financial officer mark vendetti has resigned cindy thomassee francesca’s® current vp of accounting has been appointed to the role of interim cfo share thislinkedintwitterfacebookgoogleemailprintlike thislike loadingfollow cfo moves via email join the  people that receive this update by email every week enter your email address to subscribe to this blog and receive notifications of new posts by email email address sign up for the cfo search report cfo search report a follow on to cfo moves provides information on cfo career opportunities in the market cfo search report provides eligible cfos with more information on the career opportunities identified in cfo moves cfo search report will provide monthly updates to eligible cfos only to apply to join and receive this exclusive monthly report please click this link ps  only qualified cfos will be accepted to receive this exclusive monthly report samuel dergel samuel is an executive search consultant and cfo  financial executive search specialist with dergel executive search samuel and his team prepares this blog weekly so you can have one comprehensive source for cfo moves across the usa we track cfo moves in our quest to be the most knowledgeable and up to date executive search firm focusing on the chief financial officer if you are a company that would like help with your next cfo hire are a cfo that is looking to hire the right deputies for your team or are a cfo looking for your next move feel free to contact us telephone  7 email samueldergelcfocom twitter dergelcfofollow years later looking back at my career reboot httpstcodotfzjkz by dergelcfo on linkedin   are you a cfo with something to say about us taxreform    rt cfo penn west cfo and two deputies charged with fraud httpstcoblmacgrm httpstcooa7gnxlfu   this weeks cfo moves includes movement at liquidrobotics kohls marinsoftware and  other cos… httpstcovazpzbq   rt oracleerpcloud cfos which quality best describes your style see what else dergelcfo thinks makes a great cfo httpstcotlweah…    archives archives select month july  june  may  april  march  february  january  december  november  october  september  august  july  june  may  april  march  february  january  december  november  october  september  august  july  june  may  april  march  february  january  december  november  october  september  august  july  june  may  april  march  february  january  december  november  october  september  august  july  june  may  april  march  february  january  december  november  october  september  august  july  june  may  april  march  february  january  december  november  october  september  emaillinkedinrsstwitter   samuel dergel executive search consultant and cfo search specialist all rights reserved send to email address your name your email address cancel post was not sent  check your email addresses email check failed please try again sorry your blog cannot share posts by email d bloggers like this gary l sender  chief financial officer at nabriva therapeutics plc news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink gary l sender chief financial officer at nabriva therapeutics plc overview in the news relationships paths education career history public holdings gary l sender chief financial officer at nabriva therapeutics plc overview age  born  notable companies nabriva therapeutics ag nabriva therapeutics plc synergy pharmaceuticals inc number of relationships this person is connected to  people in the news see more globenewswire may   nabriva appoints gary sender as chief financial officer business wire april 7  synergy pharmaceuticals announces resignation of chief financial officer business wire march   synergy pharmaceuticals exchange agreements to reduce  of senior notes outstanding business wire november   synergy pharmaceuticals appoints gary sender as chief financial officer relationships see details colin broom chief executive officer  director at nabriva therapeutics ag robert l crotty secretary  general counsel at nabriva therapeutics plc elyse g seltzer chief medical officer at nabriva therapeutics ag chau quang khuong private equity partner at orbimed advisors llc francesco maria lavino chief commercial officer at nabriva therapeutics plc thomas lembck chief information officer at nabriva therapeutics plc daniel d burgess venture partner biotechnology investment at sv life sciences advisers llp axel bolt investment advisor at hbm partners ag investment management charles rowland jr former president  chief executive officer at aurinia pharmaceuticals inc george harrison talbot professional at talbot advisors llc see  more listings with relsci professional start my free trial ➤ see  more paths to gary l sender gary l sender you connections via relationship science gary l sender sync your contacts to see how you can connect with gary l sender start my free trial ➤ see more educational background   carnegie mellon university carnegie mellon university challenges the curious and passionate to imagine and deliver work that matters a private global research university carnegie mellon stands among the worlds most renowned educational institutions and sets its own coursewith cuttingedge brain science pathbreaking performances innovative startups driverless cars big data big ambitions nobel and turing prizes handson learning and a whole lot of robots cmu doesnt imagine the future they create it   boston university boston university most commonly referred to as bu is a private research university located in boston massachusetts the university is nonsectarian but is historically affiliated with the united methodist church the university has more than  faculty members and  studentsand is one of bostons largest employers it offers bachelors degrees masters degrees and doctoral degrees and medical and dental degrees through  schools and colleges on two urban campuses the main campus is situated along the charles river in bostons fenwaykenmore and allston neighborhoods while the boston university medical campus is in bostons south end neighborhood bu also operates 7 study abroad programs in over  cities in over  countries and has internship opportunities in  different countries including the united states and abroad career history chief financial officer   current nabriva therapeutics ag nabriva therapeutics ag is a clinicalstage biopharmaceutical company it engages in the research and development of novel antibiotics to treat infections with a focus on the pleuromutilin class of antibiotics the company was founded by rodger novak in october  and is headquartered in vienna austria chief financial officer current nabriva therapeutics plc nabriva therapeutics plc is a holding company which operates as a clinicalstage biopharmaceutical firm it engages in the research and development of novel antibiotics to treat serious infections with a focus on the pleuromutilin class of antibiotics the company was founded on march   and is headquartered in dublin ireland chief financial officer  executive vice president    synergy pharmaceuticals inc synergy pharmaceuticals inc is a biopharmaceutical company which focuses on the development and commercialization of novel gastrointestinal therapies its product includes plecanatide and dolcanatide the company was founded by kunwar shailubhai on november   and is headquartered in new york ny senior vice presidentfinance    shire plc inactive shire is a global specialty pharmaceutical company marketing products to defined customer groups specialist doctors sales and marketing is a core shire competence shire combines investment in product development with careful attention to risk management shire currently focuses on three therapeutic areas  central nervous system disorders cns gastrointestinal gi and renal diseases shire has particular expertise in adhd as a result of its development and marketing of the leading brand in the us market adderall and the new once a day version adderall xr the group has a sales and marketing infrastructure with a broad portfolio of products targeting the us canada uk republic of ireland france germany italy and spain shire covers other significant pharmaceutical markets indirectly through distributors they have already appointed such distributors including australia denmark finland hong kong israel malaysia norway philippines singapore south africa south korea and thailand it is founded in  chief financial officer vice presidentfinance  administration prior tengion inc tengion inc is a regenerative medicine company focused on discovering developing manufacturing and commercializing of neoorgans and products tengion was founded by steven nichtberger and david i scheer on july   and is headquartered in winstonsalem nc public holdings restricted data only for relsci professional users start my free trial ➤ see more other affiliations gary l sender is affiliated with nabriva therapeutics ag nabriva therapeutics plc synergy pharmaceuticals inc shire plc inactive tengion inc youve reached your  free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ gary sender chief financial officer nabriva therapeutics timesjavascript is disabled market profiles login sign up login sign up   edit person gary sender chief financial officer at nabriva therapeutics location philadelphia pa add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop gary sender chief financial officer at nabriva therapeutics location philadelphia pa add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop gary sender serves as chief financial officer at nabriva gary sender has over  years of financial leadership experience in the pharmaceutical and biopharmaceutical industries most recently as chief financial officer and evp at synergy pharmaceuticals from  mr sender served as senior vice president finance at shire plc supporting its specialty pharmaceuticals business and subsequently its global commercial businesses he was responsible for financial management and support of all commercial areas of shire’s  billion specialty pharmaceutical and rare disease businesses with an emphasis on resource allocation financial forecasting business cases and ma prior to joining shire he was the founding cfo of tengion – a biotechnology company in the field of regenerative medicine mr sender spent  years in a number of leadership roles within merck including investor relations ma finance treasury and divisional financial management  companies in career na related markets  colleagues na related investments alias na industry rd in biotech environmental and various industries no marketing product yet tags finance financial analysis startups pharmaceutical industry topics of influence web site na careers achievements investments related people edit view all gary sendercareer  may nabriva therapeutics chief financial officer nov to apr synergy pharmaceuticals chief financial officer jun to jun shire pharmaceuticals senior vice president finance competencies edit view all gary sendereducation  7 carnegie mellon university finance  boston university questrom school of business finance general edit gary senderachievements and recognitions add milestone no milestones has been recorded for gary sender edit gary senderlinks add link no links has been recorded for gary sender gary senderinvestmentsacquisitions no investments has been recorded for gary sender gary senderinvestments representing others no investment reps has been recorded for gary sender gary senderrelated people colleagues at nabriva therapeutics francesco maria lavino chief commercial officer jul steven gelone chief development officer dec colin broom chief executive officer sep david chiswell director non executive jun view all peers 7 wilco groenhuysen chief financial officer of novocure michael gandy chief financial officer of invuity james h mackaness chief financial officer of invuity richard harrison chief financial officer of glaukos sukhi jagpal chief financial officer of pronai therapeutics thomas griffin chief financial officer of entellus medical view all gary senderrecommended market profiles healthcare ipo companies  or more employees  companies gary sender executive vice president and chief financial officer synergy pharmaceuticalsphoto business wire  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street gary sender executive vice president and chief financial officer synergy pharmaceuticalsphoto business wire business wire nov    am est synergy pharmaceuticals inc nasdaqsgyp a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal gi therapies today announced that gary sender has joined the company as executive vice president and chief financial officer mr sender will be responsible for leading synergys financial strategy and operations supporting all functions of the organization this smart news release features multimedia view the full release here httpwwwbusinesswirecomnewshomeen gary sender executive vice president and chief financial officer synergy pharmaceuticalsphoto business wire gary is a strong leader whose broad experience in small and larger specialty pharmaceutical organizations uniquely qualifies him to lead and build our financial operations as we enter a transformative period in our history said gary s jacob phd chairman and ceo of synergy having previously managed financial planning and analysis and strategic growth initiatives of shires global commercial businesses gary has a thorough understanding of the exciting opportunities from which synergy is poised to benefit im confident he can add significant value as we prepare to successfully enter a growing and dynamic gi market i was immediately attracted to the excitement and energy around synergy said gary sender the company is approaching a period of immense growth and opportunity with anticipated regulatory filings next year and the commercial launch of plecanatide planned for early  i look forward to working with the synergy team to successfully execute on these goals and continue to drive significant shareholder return gary sender has over  years of financial leadership experience in the pharmaceutical and biopharmaceutical industries most recently at shire plc from  mr sender served as senior vice president finance supporting its specialty pharmaceuticals business and subsequently its global commercial businesses he was responsible for financial management and support of all commercial areas of shires  billion specialty pharmaceutical and rare disease businesses including the gastroenterology business unit with an emphasis on resource allocation financial forecasting business cases and ma prior to joining shire he was the founding cfo of tengion  a biotechnology company in the field of regenerative medicine mr sender spent  years in a number of leadership roles within merck including investor relations ma finance treasury and divisional financial management mr sender holds a bachelors degree in finance and information systems from boston university and a masters degree in industrial administration mba with a concentration in finance from carnegiemellon university if you liked this article you might like  biotech stocks on readers minds we answer questions about biodelivery sciences dynavax technologies and synergy pharmaceuticals bret jensen jul    am edt biotech stocks finally stage breakthrough the sector decisively has pushed through upward resistance levels in place for many months bret jensen jun    am edt comcast synergy pharmaceuticals chipotle blackstone group mad money lightning round jim cramer is bullish on comcast synergy pharmaceuticals chipotle and blackstone group but hes bearish on sierra wireless scott rutt jun 7   am edt go inside amazons disruptive deal for whole foods cramers mad money recap friday 7 amazon wants to entertain and clothe  and now feed  every american cramer names the winners and the losers in this deal scott rutt jun    pm edt trending worst performing tech stocks amzn amd mu wdc jim cramer nails starbucks big decline warns again of downside to  us steel shares are being torched thanks to one stock analyst intel is wellpositioned for growth as long as amd doesnt get in the way amazon and general electric are fridays smoking hot tickers amzn tsla sbux ge aapl x advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers